Jul. 13 at 11:54 AM
$NKTR QTTB primary endpoint numbers similar to rezpeg.
Except QTTB's numbers were open label, which almost always artificially inflates results. At best, you probably have a drug equivalent to rezpeg but without the durability.
And also zero value is currently being assigned to NKTR for AA, so stock shouldn't go down regardless. But as we know, market often irrational in short term.
